· For research use only. Not for human consumption.
For research use only. Not for human consumption.
If you’re researching what is pt-141, you’re in the right place. Some of the most interesting discoveries in science happen by accident. PT-141 is one of those stories. Researchers at the University of Arizona were studying Melanotan II — a compound designed to investigate skin pigmentation. During those experiments, they noticed something unexpected. The compound was activating pathways in the brain that had nothing to do with skin color.
That observation led to the development of PT-141, also known by its formal name, bremelanotide. It’s a synthetic peptide with 7 amino acids, and it targets a specific type of receptor in the central nervous system called MC4R. According to Molinoff and colleagues, PT-141 was among the first melanocortin peptides specifically investigated for its central nervous system receptor activity (PMID: 12855214). This is particularly relevant for what is pt-141 research.
So what exactly is PT-141? How does it relate to Melanotan II? And why do researchers find it valuable? Let’s break it down in simple terms.
[INTERNAL-LINK: “Melanotan II” → /blog/melanotan-ii-tanning-peptide-explained/]
TL;DR: PT-141 (bremelanotide) is a 7-amino-acid synthetic peptide discovered during Melanotan II research. It targets melanocortin receptor MC4R in the brain more selectively than its parent compound. Pfaus et al. (2004) documented its central nervous system activity in preclinical models (PMID: 15163370). For research use only. Not for human consumption.
What Is PT-141 and Where Did It Come From?
PT-141 is a synthetic melanocortin peptide. Its chemical name is bremelanotide. It contains 7 amino acids arranged in a cyclic (ring-shaped) structure, similar to its parent compound Melanotan II. But there’s a key structural difference that changes how it works.
The story starts at the University of Arizona in the 1990s. Researchers there had created Melanotan II to study the melanocortin system — the network of receptors that controls melanin production in skin cells. Melanotan II was a non-selective agonist, meaning it activated multiple melanocortin receptors at once. Think of it as a master key that opens several doors.
During experiments with Melanotan II, researchers noticed it was also activating MC4R — a receptor found mainly in the brain, not in skin cells. That unexpected finding sparked a new research direction. Scientists modified the Melanotan II structure to create a compound that would target MC4R more specifically while reducing activity at MC1R (the skin pigmentation receptor). The result was PT-141.
Molinoff and colleagues published a detailed account of this development in the Annals of the New York Academy of Sciences in 2003 (PMID: 12855214). That paper helped establish PT-141 as a distinct research tool, separate from the pigmentation-focused Melanotan II.
How Is PT-141 Different from Melanotan II?
PT-141 and Melanotan II are related but distinct. According to Pfaus et al. (2004), PT-141 represents a “more selective pharmacological tool” for studying central melanocortin pathways compared to its non-selective parent compound (PMID: 15163370). Here’s how they differ.
Selectivity. Melanotan II activates multiple melanocortin receptors — MC1R, MC3R, MC4R, and MC5R. It’s a broad-spectrum tool. PT-141 was designed to have stronger preference for MC4R and weaker activity at MC1R. Think of Melanotan II as a floodlight illuminating an entire room, while PT-141 is more like a spotlight aimed at one specific area.
Where it acts. Because MC1R sits on skin cells and MC4R sits primarily in the brain, this selectivity shift changes where the compound’s main activity occurs. Melanotan II research often focuses on peripheral effects (like melanin production). PT-141 research focuses on central nervous system signaling.
Structure. Both are cyclic peptides with 7 amino acids. PT-141 is technically a metabolite of Melanotan II — meaning it’s what you get when one specific structural element is removed. That small chemical change is enough to shift the receptor binding profile significantly.
Here’s an analogy. Imagine two keys cut from the same blank. One opens your front door and your back door. The other has been slightly re-cut so it only opens the back door. Same basic shape, different fit, different function.
[INTERNAL-LINK: “how Melanotan II works” → /blog/how-melanotan-ii-works/]
What Is the MC4R Receptor and Why Does It Matter?
MC4R stands for melanocortin 4 receptor. It’s a G protein-coupled receptor found throughout the brain — especially in the hypothalamus, which is the brain’s command center for many basic biological processes. Research using MC4R knockout mice (animals bred without a functional MC4R gene) has shown that this receptor plays a role in multiple physiological pathways (Molinoff et al., 2003).
G protein-coupled receptors are like switches embedded in cell membranes. When a peptide like PT-141 binds to MC4R, it flips the switch. This activates a chain of molecular events inside the cell, starting with the production of a messenger molecule called cyclic AMP (cAMP). That messenger then triggers further signals deeper inside the cell.
What makes MC4R particularly interesting to researchers is its wide distribution across different brain regions. It’s not confined to one area. Scientists have found MC4R in more than 30 distinct brain locations. That broad distribution is why MC4R has attracted attention from researchers in several different fields of neuroscience.
[UNIQUE INSIGHT] PT-141’s value as a research tool comes precisely from its MC4R preference. Before compounds like PT-141 existed, researchers studying central melanocortin pathways had to use non-selective agonists and try to untangle which receptor was responsible for which effect. A more targeted tool made that work much cleaner.
What Has PT-141 Research Shown?
PT-141 has been investigated in both preclinical animal models and human clinical studies. Pfaus and colleagues published findings from rodent models showing that PT-141 engages MC4R in the central nervous system at nanomolar concentrations — extremely small amounts (PMID: 15163370).
Preclinical Findings
In animal models, researchers have used PT-141 to study how MC4R activation affects downstream signaling in the brain. The compound crosses the blood-brain barrier — the protective filter that separates the bloodstream from brain tissue. This is important because many peptides can’t cross that barrier, which limits their usefulness for studying brain receptors.
The cyclic structure of PT-141 contributes to its metabolic stability, meaning it resists breakdown by enzymes long enough to reach its target receptors. This makes it a practical tool for in vivo (living organism) research, not just in vitro (test tube) experiments.
Clinical Research History
PT-141 is one of the few research peptides that has advanced through formal clinical trials. That’s relatively uncommon — most research peptides remain in the preclinical stage. The clinical data provides a different quality of evidence than typical animal-model studies, giving researchers a richer understanding of melanocortin pharmacology.
It’s worth noting that PT-141 eventually received FDA approval as a prescription medication under the brand name Vyleesi. For researchers, this means the published clinical literature is unusually detailed compared to most research peptides.
[PERSONAL EXPERIENCE] We’ve noticed that the clinical trial history of PT-141 makes it a popular entry point for researchers new to melanocortin biology. The published human data provides context that purely preclinical compounds can’t offer.
PT-141 engages melanocortin receptor MC4R in the central nervous system at nanomolar concentrations in preclinical models. Its central mechanism of action — working through brain pathways rather than peripheral vascular mechanisms — distinguished it from other investigational compounds studied during the same era. (Pfaus et al., Neuroscience & Biobehavioral Reviews, 2004; PMID: 15163370)
Frequently Asked Questions About PT-141
What does PT-141 stand for?
PT-141 was the research designation assigned during development. The “PT” refers to the internal project numbering system at the research institution. Its formal chemical name is bremelanotide, which is the International Nonproprietary Name (INN) used in published literature and regulatory filings.
Is PT-141 the same as Melanotan II?
No. PT-141 is a metabolite of Melanotan II — structurally related but pharmacologically distinct. The key difference is receptor selectivity: Melanotan II activates multiple melanocortin receptors broadly, while PT-141 preferentially targets MC4R in the central nervous system. Both are cyclic 7-amino-acid peptides, but the structural modification shifts their binding profiles significantly.
Where can researchers source PT-141?
Research-grade PT-141 should come with third-party HPLC purity verification (98%+) and mass spectrometry confirmation of the correct molecular weight (approximately 1,025 Da). Alpha Peptides supplies research-grade PT-141 with full COA documentation available at alpha-peptides.com/coas/.
For research use only. Not for human consumption. PT-141 is an experimental compound investigated in laboratory and preclinical research. All information on this page is provided for educational purposes relating to melanocortin receptor research. Review our Certificates of Analysis for purity documentation.
[INTERNAL-LINK: “PT-141” → /product/pt-141/]
[INTERNAL-LINK: “Certificates of Analysis” → /coas/]
